Our findings also suggest that the cytotoxic activity of such a population may be further enhanced by IL-21 treatment, and indeed it has been reported that a combination of IL-21 with low dose IL-2 improves outcomes in a murine melanoma model, in part by enhancing the anti-tumor activity of CD8+ T cells [29]. This evidence concerns the gene CD8A and melanoma.